Avid Bioservices, Inc., a subsidiary of Peregrine Pharmaceuticals, Inc., has extended its commercial manufacturing supply agreement with Halozyme Therapeutics, Inc. Under the terms of the contract amendment, Avid could manufacture as many as 20 runs per year during the next five years of a recombinant human enzyme that is the active ingredient in Halozyme's marketed products, Hylenex and Cumulase. Avid began manufacturing commercial product for Halozyme under cGMP in 2004.

"We are pleased to extend our contract with Avid to manufacture our recombinant human enzyme that is a key ingredient in Hylenex and Cumulase," said William Fallon, vice president of manufacturing and operations at Halozyme. "Avid's proven capabilities in cGMP manufacturing support our ability to increase sales of both marketed products."

"We are delighted that Halozyme has re-confirmed their confidence in Avid's capabilities by extending the term of the agreement for five additional years, while also significantly expanding its potential scope," said Richard Richieri, senior vice president of bioprocess development and manufacturing at Avid. "We have had a very productive relationship with Halozyme over the past few years and are pleased to be the primary manufacturer for this important commercial product and technology."

News from our sister sites